Lupin and Biomm Enter into a Distribution and Marketing Agreement for Pegfilgrastim in Brazil

Global pharma major, Lupin Limited (Lupin) announced today that they have entered into an exclusive distribution and marketing agreement with Biomm SA in Brazil. Under the terms of agreement, Biomm will distribute and market biosimilar Pegfilgrastim in Brazil.

Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar to Neulasta® (pegfilgrastim) through a filing using the 351(k) pathway. Pegfilgrastim is indicated to reduce the duration of neutropenia and the Incidence of febrile neutropenia in patients receiving chemotherapy.

Shares of Lupin Limited was last trading in BSE at Rs. 873.10 as compared to the previous close of Rs. 875.70. The total number of shares traded during the day was 53346 in over 2523 trades.

The stock hit an intraday high of Rs. 884.45 and intraday low of 870.85. The net turnover during the day was Rs. 46771477.00.

Source : Equity Bulls

Keywords

LupinLimited INE326A01037 Pharmaceuticals BiommSA Brazil MarketingAgreement DistributionAgreement Pegfilgrastim Biosimilar